QT Imaging Holdings enters the post-earnings session with a contradictory setup: the stock climbed 12% last week on a revenue beat and a guidance reaffirmation, yet short sellers responded by accelerating their positions at the fastest weekly pace in over a month.
The core tension is in how shorts and bulls interpreted the same results differently. Q1 EPS came in at -$0.25, badly missing the -$0.14 estimate. Revenue of $6.53M edged past the $6.45M consensus. Management reaffirmed full-year 2026 sales guidance of $39M, above the $38.65M street estimate. The stock closed at $7.59 on Tuesday, up 6.2% on the day. Yet underneath that rally, short sellers were adding, not retreating.
Short interest jumped 21.8% week-on-week to 2.64% of the free float — a level that has more than doubled from the 1.3% range visible at the start of April. The one-month change is even sharper at 51.8%, reflecting a steady build that began in early April and accelerated into the earnings print. At 314,700 shares short, the absolute position remains modest for a stock this size, but the rate of change is the more notable signal here. Cost to borrow has been volatile — it spiked to 5.9% on April 29 before easing to 2.37% — and the lending market is tighter than it looks: availability has been squeezed progressively since early April, and the ORTEX short score has climbed from the low 60s to 65.9 over just the past two weeks, now ranking in the 7th percentile of the universe. That ranking reflects how elevated the combined short-positioning signals are relative to peers. Days to cover of 8.6 mean a meaningful squeeze could develop slowly rather than violently.
The bull case rests on execution and scale. FY2025 saw 40 scanners shipped — more than triple the 2024 figure — with revenue of $18.9M beating guidance of $18M. The UAE distribution agreement signed in January with Al Naghi Medical carries minimum order quantities totalling 43 scanners over three years, representing over $24M in contracted minimum revenue. That deal, on top of the Canon-linked NXC Imaging US distribution partnership and Gulf Medical coverage in Saudi Arabia, gives the revenue story a degree of visibility unusual for a company this size. The bear case is straightforward: QTI is still deeply unprofitable, with FY2025 net loss of $21.1M on $18.9M of revenue. The EPS miss this quarter, nearly twice the consensus loss, is a reminder that scaling hardware while building a parallel SaaS cloud platform is capital-hungry. Market cap of around $91M leaves little room for multiple slippage.
Ownership concentration amplifies the story. Lynrock Lake holds 9.6% of shares, and Alyeska Investment Group built a 5.6% position — adding 702,777 shares in the period ending December 2025 — making it the largest single filing-period buy on the cap table. James Greene, a director, added 418,721 shares reported as of March 20, 2026. The most recent insider trade in the dataset is Founder and Chairman Avishay Katz buying 24,107 shares in January at $6.43. That purchase was made above current levels and now sits modestly in the money at $7.59. Insider activity has been exclusively on the buy side across all disclosed transactions, though the most recent trade is now 112 days old — stale enough that the near-term signalling value is limited. No analyst coverage data is available in the ORTEX dataset, which means the stock is trading on fundamentals and flow rather than sell-side catalysts.
The next data point to watch is whether short interest continues climbing post-earnings — a second consecutive week of additions would suggest that some market participants view the EPS miss and ongoing cash burn as more significant than the guidance reaffirmation and revenue beat. The RSI at 68.1 means price momentum is elevated but not yet extended, leaving the question of whether the rally has further room or whether the rebuilding short base eventually finds traction against the profitability timeline.
See the live data behind this article on ORTEX.
Open QTI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
